SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 4184-4190.
  • 2
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333: 1540-1545.
  • 3
    Lee FY, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol. 2008; 63: 157-166.
  • 4
    Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001; 7: 1429-1437.
  • 5
    Younes A. Paclitaxel-based treatment of lymphoma. Semin Oncol. 1999; 26( 1 suppl 2): 123-128.
  • 6
    Khrapunovich-Baine M, Menon V, Yang CP, et al. Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation. J Biol Chem. 2011; 286: 11765-11778.
  • 7
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244.
  • 8
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 47: 583-621.
  • 9
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B. 1972; 34: 187-220.
  • 10
    Aghajanian C, Burris HA 3rd, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007; 25: 1082-1088.
  • 11
    O'Connor OA, Portlock C, Moskowitz C, et al. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2008; 143: 201-209.
  • 12
    Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.
  • 13
    Budman DR, Petroni GR, Johnson JL, Cooper MR, Schlossman DM, Barcos M, et al. Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol. 1997; 15: 3275-3279.
  • 14
    Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, et al. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. Cancer Invest. 2005; 23: 13-18.
  • 15
    Rizzieri DA, Sand GJ, McGaughey D, et al. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer. 2004; 100: 2408-2414.
  • 16
    Casasnovas RO, Haioun C, Dumontet C, et al. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Haematologica. 2000; 85: 502-507.
  • 17
    Press OW, LeBlanc M, O'Rourke TJ, et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol. 1998; 16: 574-578.
  • 18
    Wilson WH, Chabner BA, Bryant G, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol. 1995; 13: 381-386.
  • 19
    Younes A, McLaughlin P, Romaguera J, et al. Taxol plus topotecan plus rituximab (TTR) with G-CSF support: an effective salvage program for the treatment of patients with relapsed/refractory aggressive B-cell non-hodgkin lymphoma (NHL) who failed CHOP-like and platinum-based therapy. Session type: oral session [Abstract]. Blood. 2003; 102: abstract 489.
  • 20
    Younes A, Preti HA, Hagemeister FB, et al. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2001; 12: 923-927.
  • 21
    Younes A, Sarris A, Melnyk A, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1995; 13: 583-587.
  • 22
    Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004; 101: 1835-1842.
  • 23
    Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 3786-3792.
  • 24
    Wenger C, Stern M, Herrmann R, Rochlitz C, Pless M. Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? Leuk Lymphoma. 2005; 46: 71-75.
  • 25
    Vacirca J, Tabbara I, Acs P, Shumaker G. Bendamustine + rituximab as treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma [Abstract]. Blood. 2010; 116: abstract 2806.
  • 26
    Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002; 13: 1285-1289.